These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17256723)

  • 1. Keratin-18 as a marker of steatohepatitis.
    Gonzalez-Quintela A; Lojo S; Otero E; Perez LF
    Hepatology; 2007 Feb; 45(2):545. PubMed ID: 17256723
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum cytokeratin-18 fragment level: a noninvasive biomarker for not only nonalcoholic steatohepatitis, but also alcoholic steatohepatitis.
    Li X; Zhang Y; Wu K; Fan D
    Hepatology; 2010 May; 51(5):1865-6. PubMed ID: 20041411
    [No Abstract]   [Full Text] [Related]  

  • 3. One step at a time: identification and validation of biomarkers for nonalcoholic steatohepatitis.
    Talwalkar JA
    Hepatology; 2009 Oct; 50(4):1000-3. PubMed ID: 19787817
    [No Abstract]   [Full Text] [Related]  

  • 4. Is biopsy always necessary? Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity.
    Emanuele E
    Hepatology; 2008 Dec; 48(6):2086-7; author reply 2087. PubMed ID: 19030167
    [No Abstract]   [Full Text] [Related]  

  • 5. Noninvasive diagnosis of nonalcoholic fatty liver disease using serum biomarkers.
    Mitry RR; De Bruyne R; Quaglia A; Hughes RD; Dhawan A
    Hepatology; 2007 Dec; 46(6):2047-8; author reply 2048. PubMed ID: 18046726
    [No Abstract]   [Full Text] [Related]  

  • 6. An apoptosis biomarker for prediction of nonalcoholic steatohepatitis.
    Bantel H; Bahr MJ; Schulze-Osthoff K
    Hepatology; 2009 Sep; 50(3):991. PubMed ID: 19593820
    [No Abstract]   [Full Text] [Related]  

  • 7. Commentary on "Cytokeratin 18, a Marker of Cell Death, is Increased in Children With Suspected Nonalcoholic Fatty Liver Disease".
    Yilmaz Y; Dolar E; Ulukaya E
    J Pediatr Gastroenterol Nutr; 2009 Sep; 49(3):371; author reply 371-2. PubMed ID: 19707105
    [No Abstract]   [Full Text] [Related]  

  • 8. [Laboratory data for assessment of nutrition in liver disease--with special reference to alcoholic hepatitis and nonalcoholic steatohepatitis (NASH)].
    Sugimoto M
    Rinsho Byori; 2003 Oct; Suppl 127():45-51. PubMed ID: 14653214
    [No Abstract]   [Full Text] [Related]  

  • 9. Robust detection of liver steatosis and staging of NAFLD by an improved ELISA for serum cytokeratin-18 fragments.
    Bantel H; John K; Schulze-Osthoff K
    Am J Gastroenterol; 2014 Jan; 109(1):140-1. PubMed ID: 24402545
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD.
    Fitzpatrick E; Mitry RR; Quaglia A; Hussain MJ; DeBruyne R; Dhawan A
    J Pediatr Gastroenterol Nutr; 2010 Oct; 51(4):500-6. PubMed ID: 20808246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum markers of hepatocyte apoptosis: current terminology and predictability in clinical practice.
    Tiniakos DG; Papatheodoridis GV
    Hepatology; 2010 Feb; 51(2):717-8. PubMed ID: 19918977
    [No Abstract]   [Full Text] [Related]  

  • 12. Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments.
    Yilmaz Y; Kurt R; Kalayci C
    Biomark Med; 2010 Oct; 4(5):743-5. PubMed ID: 20945987
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum M30 levels: a potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels.
    Yilmaz Y; Ulukaya E; Dolar E
    Hepatology; 2009 Feb; 49(2):697; author reply 697. PubMed ID: 19035337
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
    Ito S; Yukawa T; Uetake S; Yamauchi M
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caspase-cleaved keratin 18 as a biomarker for non-alcoholic steatohepatitis (NASH) - the need for correct terminology.
    Linder S
    J Hepatol; 2011 Dec; 55(6):1467. PubMed ID: 21763667
    [No Abstract]   [Full Text] [Related]  

  • 16. "Defragmenting" the noninvasive diagnosis of nonalcoholic steatohepatitis: hopes from cytokeratin-18.
    Yilmaz Y
    Hepatology; 2009 Sep; 50(3):990-1. PubMed ID: 19492431
    [No Abstract]   [Full Text] [Related]  

  • 17. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.
    Munteanu M; Ratziu V; Morra R; Messous D; Imbert-Bismut F; Poynard T
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):187-91. PubMed ID: 18568141
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pathological and clinical analysis of nonalcoholic steatohepatitis].
    Pan HY; Ye RX; Shi JP; Guo XF
    Zhonghua Gan Zang Bing Za Zhi; 2003 Jun; 11(6):384. PubMed ID: 12837234
    [No Abstract]   [Full Text] [Related]  

  • 19. [Determination of cholylglycine in alcoholic hepatopathies. Clinical usefulness].
    Pagani A; Pranzo A; Galante T
    Minerva Dietol Gastroenterol; 1985; 31(1):25-31. PubMed ID: 4000510
    [No Abstract]   [Full Text] [Related]  

  • 20. Invasive and non-invasive investigations for non-alcoholic steatohepatitis (NASH): the need for biochemical markers.
    Ahmed MH
    Scand J Gastroenterol; 2006 Mar; 41(3):372. PubMed ID: 16497631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.